Project title: CONNECT-1903: A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion.
Institute: ANZCHOG
Funding: $54,095 (July 2020 – December 2027)
Funding partners: Medical Research Future Fund (MRFF)
Love for Lachie
Research Pillar: Translate
Cancer Type: Brain and CNS (High-grade glioma with NTRK fusion)
Project title: Targeted Paediatric High-Grade Glioma Therapy (TarGet) clincal trial
Institute: ANZCHOG
Funding: $350,000 (December 2024 – December 2031)
Funding partners: Target collaborative
RCD foundation
The Cure Starts Now
My Room
Childrens Cancer Foundation
MHF Centre for Brain Cancer Research
Research Pillar: Translate
Cancer Type: Brain and CNS (High-grade glioma; Diffuse Intrinsic Pontine Glioma)
High grade gliomas (HGG) are fast growing, aggressive brain cancers and if they recur after initial treatment, there are no effective treatment options. Many children with HGG have a mutation in the NTRK gene. Excitingly, a novel agent larotrectinib has showed to be effective in treating other cancers with NTRK mutations. This study will investigate if a can be of benefit in children diagnosed with HGG containing a NTRK gene. CONNECT-1903 is an international clinical trial that will examine, for the first time, how well the larotrectinib is tolerated and its effectiveness to shrink these tumours in children diagnosed with HGG containing NRTK fusions.
Read more: CONNECT-1903: A new trial for brain cancer now available in Australia
CONNECT-1903 will open at Perth Children’s Hospital, Sydney Children’s Hospital and Queensland Children’s Hospital. It is sponsored by the Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) and is the first trial available from the international brain cancer consortia CONNECT.
This research project has received additional collaborative funding by the Australian Government’s Medical Research Futures Fund and Love for Lachie.